s6y

Boundless Bio, Inc.

Ticker
BOLD
CIK
1782303
Industry
Pharmaceutical Preparations

Financials 11

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 11 financials filings

News 20

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 20 news filings

Ownership 84

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 84 ownership filings

Prospectus 17

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. S-4/A Registration of securities issued in business combination transactions
  3. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  4. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  5. S-4 Registration of securities issued in business combination transactions
  6. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  7. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  8. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  9. S-3 Registration statement for specified transactions by certain issuers
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 17 prospectus filings

Proxies 4

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements

Other 30

  1. SCHEDULE 13G/A
  2. EFFECT Notice of Effectiveness
  3. SCHEDULE 13G
  4. SCHEDULE 13G
  5. SCHEDULE 13G/A
  6. SCHEDULE 13G
  7. ARS Annual report to security holders
  8. SCHEDULE 13G/A
  9. SCHEDULE 13G/A
  10. SCHEDULE 13G

All 30 other filings